Mitchener Stephen 4
4 · Karyopharm Therapeutics Inc. · Filed Mar 2, 2023
Insider Transaction Report
Form 4
Mitchener Stephen
SVP, Chief Business Officer
Transactions
- Award
Common Stock
2023-02-28+60,000→ 134,670 total - Sale
Common Stock
2023-03-01$3.03/sh−6,357$19,257→ 128,313 total
Footnotes (3)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.
- [F2]Includes 2,147 shares and 1,977 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2022 and October 31, 2022, respectively.
- [F3]This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.